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Abstract
Human visceral leishmaniasis (HVL) is the most severe clinical form of a spectrum of neglected tropical diseases caused by protozoan
parasites of the genus Leishmania. Caused mainly by L. donovani and L. infantum/chagasi, HVL accounts for more than 50 000 deaths
every year. Drug therapy is available but costly, and resistance against several drug classes has evolved. Here, we review our current
understanding of the immunology of HVL and approaches to and the status of vaccine development against this disease.
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Introduction
Proposals and broad issues regarding a research agenda
for the development of vaccines against the leishmaniases
have recently been discussed [1–6]. Fatal human visceral
leishmaniasis (HVL) caused by L. donovani and L. infantum/
chagasi in the old world and L. infantum/chagasi in the New
World [7,8] is the focus of this review. L. infantum/chagasi
maintains a zoonotic cycle mostly involving canine hosts, and
canine visceral leishmaniasis (CVL) is a veterinary problem in
its own right [9]. Reducing the incidence of CVL is a promis-
ing control strategy for zoonotic HVL [10,11]. However,
L. donovani has an anthroponotic cycle [12,13] (e.g. in India
where HVL is known locally as kala azar). Patients treated
and cured for HVL caused by L. donovani may subsequently
develop post kala azar dermal leishmaniasis (PKDL), charac-
terized by nodular skin lesions in which parasites can be
detected [14]. Parasite persistence during PKDL is thought
to be involved in igniting epidemics of HVL [15]. The epide-
miological relevance of subclinical infection is only clear in
dogs, where animals with subclinical infection can transmit
parasites [16–18]. Our understanding of the relative contri-
bution of subclinical vs. PKDL cases to the epidemiology of
HVL has an important bearing on the design of elimination
campaigns. Whereas both therapeutic and prophylactic vac-
cines each have their place in control programmes, prophy-
lactic or possibly post-exposure vaccination (and vector
control) may be essential if subclinical infections play a domi-
nant role in maintaining the disease cycle.
Immunology
The immunology and immunopathology of visceral leishman-
iasis in man, dog and in experimental rodent models (EVL)
has been extensively studied, and in-depth reviews are
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available on this topic [10,19–22]. Central to our ability to
manipulate host protective immunity is an understanding of
the life cycle of Leishmania in its mammalian host and the
impact on this of various host defence mechanisms. Surpris-
ingly, this is less complete than might be expected, with a
number of questions related to vaccine success still to be
answered (Fig. 1).
Although HVL is characterized by hypergammaglobulina-
emia (associated with polyclonal B cell activation; [23]) and
both antibody and B cells have been shown to have various
regulatory roles in EVL [24,25], the precise value of high
titre vaccine-induced antibodies has yet to be fully deﬁned.
Whereas opsonization of metacyclic promastigotes could
reduce infectious load after sandﬂy transmission, there is a
signiﬁcant body of data derived from other models of leish-
maniasis suggesting that antibodies may facilitate infection
[26,27]. Unfortunately, we have little knowledge about how
the infectious dose relates to the development of natural
immunity (i.e. sub-clinical infection) and signiﬁcantly, most
experimental vaccine studies fail to measure early parasite
load post-challenge, confounding the interpretation of pro-
tection measured at later time points. In HVL and CVL,
immune complexes may also cause glomerulonephritis [23],
though this is a factor that might only be of consideration in
relation to therapeutic vaccination. What is clear is that
most effective licensed human vaccines were developed for
infections against which antibody-mediated protection is
characteristic [28] and this fact should stimulate further
research into the relationship between vaccine-induced anti-
body responses, infectious dose and subsequently acquired
immunity.
Within hours of sandﬂy transmission, metacyclic prom-
astigotes take up intracellular residence and begin conversion
to intracellular amastigotes, from then on the only life cycle
stage of Leishmania associated with human disease. Although
recent evidence suggests that metacyclic forms can be found
in neutrophils [29], most data indicate that long-term amasti-
gote survival and replication occurs within mononuclear
phagocytes [30]. Hence, T-cell-mediated immunity targeting
either activation or killing of amastigote-infected macrophag-
es is generally regarded as the cornerstone of host resis-
tance and the main target for vaccine-induced responses
(Fig. 1). Our knowledge of these responses derives from
methodologies as diverse as serum cytokine analysis and
intravital 2-photon microscopy, but rarely are multiple over-
lapping methodologies applied in the same study, further
complicating data interpretation. In HVL, CVL and EVL,
T-cell-mediated resistance is nevertheless clearly multifac-
eted: nitrogen and oxygen radicals serve as major leishmani-
cidal effectors in macrophages [31] but other pathways may
also operate [32]; both Th1- and Th2-associated cytokines
contribute to primary and vaccine-induced resistance [33,34];
CD4+ Foxp3) IL-10+ Th1 cells [35,36] and/or natural CD4+
Foxp3+ IL-10+ Treg [37] may hinder macrophage activation;
CD8+ T cells may provide additional beneﬁcial cytokines
and/or their cytotoxic potential may allow release of
FIG. 1. A vaccinologist’s view of the Leishmania life cycle. Immune responses induced by vaccination can target metacyclic promastigotes directly,
their products (e.g. promastigote secretory gel, PSG) or sandﬂy salivary proteins to limit initial parasite establishment. Metacyclics that survive
can be targeted as amastigotes in macrophages found in skin or various systemic organs. Macrophages can be uninfected, infected or activated to
kill Leishmania amastigotes. Parasite spread between macrophages is believed to occur through cell lysis. During subclinical infection or after clini-
cal cure, immune responses maintain a state of persistent infection for the life of the host. Key questions pertaining to the role of Ab and CMI
at each stage of the infection are listed. In most cases, the relative importance of each during vaccine-induced immunity has yet to be established.
Possible transmission-blocking effects of vaccination operating in the sandﬂy host are not shown. Key: 4/8, naı¨ve CD4+ or CD8+ T cells; 1, 2, 10,
17, reg, activated CD4+ T cell subsets (note similar diversity may occur in activated CD8+ T cells, not shown); 4 m/8 m, memory CD4+ and
CD8+ T cells; macrophages, neutrophils, dendritic cells, stromal cells, metacyclic promastigotes and amastigotes are depicted with characteristic
morphology.
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amastigotes to facilitate killing by activated monocytes [38];
and effective immunity may be optimal when focused within
organized tissue structures termed granuloma [22,30].
Importantly for therapeutic vaccination (and for drug action),
progressive disease is associated with an increasing state of
immunosuppression, attributed both to the presence of
immunoregulatory cytokines, notably IL-10 and TGFb [20],
and also to destructive remodelling of lymphoid tissue [39].
Thus, interventions that alleviate the immunosuppressive
state or that stimulate more potent T-cell responses have
been increasingly seen as having potential for immunotherapy
[40]. Nevertheless, in spite of many years of investigation,
our knowledge of the mechanisms that allow life-long sub-
clinical persistence of viscerotropic species of Leishmania
either following natural infection or drug-induced cure are
very scanty [41] and consequently there are few robust and
validated correlates of protection that can be applied to
studies of vaccination in man.
Status of Vaccine Development for HVL
In spite of an estimated 500 000 cases annually (http://
www.who.int/leishmaniasis/en/), HVL has been considered an
unattractive vaccine target for industry, being primarily a dis-
ease of the poor. Yet the economic impact at household and
population level is substantial, even though the methodology
used to quantify the problem is crude [42]. HVL ranks
second only to malaria for mortality and fourth for morbidity
amongst tropical parasitic diseases [43]. Even in relation to
the projected most cost-effective combination therapy (esti-
mated at $80 [44]), treatment and related costs (which in
India surpass 10% of average household expenditure),
present a ﬁnancial burden that will force many into spiralling
poverty [45]. A vaccine (subsidized or otherwise) will need
to cost less per averted clinical case [44], and far less for a
prophylactic vaccination campaign in areas where incidence
rates are low. Low incidence also drives up the cost and
complexity associated with prophylactic vaccine trials
designed to show efﬁcacy, leading some to conclude that
testing vaccines in therapeutic trials (http://www.who.int/
vaccine_research/diseases/soa_parasitic/en/index3.html) or by
using leishmanization as a ‘challenge’ infection [46] is the
most cost-effective way to move forward.
Although the century-old practice of leishmanization, the
deliberate infection of naı¨ve people with virulent L. major, still
provides the most compelling evidence that vaccination
against leishmaniasis is feasible [46,47], the efﬁcacy of this
approach has not been shown for VL. Furthermore, whilst
many whole killed parasite vaccines have been developed
(http://www.upmc-biosecurity.org/website/resources/govt_
docs/countermeasures/hhs/hhs_jordan_rpt_accel_dev_
vac_2007.html), a recent meta-analysis of the respective
prophylactic vaccine trials yielded a disillusioning summary of
the lack of clinical efﬁcacy of these ﬁrst-generation vaccines
[5]. In contrast, therapeutic vaccine development is sup-
ported by good clinical evidence, albeit also in the context of
cutaneous or mucocutaneous leishmaniasis, because crude
parasite lysates with BCG provide an effective adjunct to
chemotherapy (for recent review see [48,49]) and treatment
with a mixture of recombinant parasite proteins and
GM-CSF combined with antimony therapy showed promise
in patients that were refractory to drug-only treatment [50].
Given the complexity of the host immune response to
vaccines, whole killed or lysed parasites may contain antigens
or other characteristics that induce non-protective as well as
protective immune responses [10,51]. Thus, second-genera-
tion vaccines, using parasite fractions or deﬁned protein
subunits, aim to reduce this complexity, and many have been
tested in models of experimental leishmaniasis (though fewer
in EVL; [1]), but only a few formulations have entered clinical
or veterinary testing (see supplementary Table S1 for a com-
prehensive summary). Only a single product (Leish-111f), a
fusion protein of three relatively conserved Leishmania pro-
teins (thiol-speciﬁc antioxidant, stress inducible protein 1 and
elongation initiation factor) formulated with MPL-SE is
entering phase II clinical testing in humans, including HVL as
a therapeutic vaccine [6,52]. Leish-111f has been shown to
have efﬁcacy in mice [53] and under the product name rLe-
ish-110f has been tested as an adjunct therapy together
with Glucantime to treat a ﬁeld population of dogs suffering
from CVL due to L. chagasi infection [54]. Vaccination was
safe and induced a 2–3-fold increase in antigen-speciﬁc prolif-
erative response in vitro after cure, but was lacking clear clin-
ical beneﬁt (though the trial was not powered to reveal
small effects). Leish-110f in the form of an experimental vac-
cine designated MML was also tested alongside recombinant
L. infantum histone H1 and hydrophilic acylated protein B1
(HASPB1 [55]) as prophylactic vaccines against experimental
CVL [56]. Dogs were vaccinated with either MML adjuvanted
with MPL-SE or H1 or HASPB1 adjuvanted with Monta-
nide-ISA 720 and subsequently challenged with 108 L. infan-
tum promastigotes. All vaccines were immunogenic, with
some interesting differences in whether infection boosted
these responses. For example, MML antibody responses
were strongly boosted, HASPB1 responses weakly so and
H1 response unaffected by infection [56]. Fewer H1 and
HASPB1 immunized dogs developed CVL symptoms (37%
and 50%, respectively) compared with control or MML-vacci-
nated dogs (71% and 75%, respectively), but larger studies
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would be required to conﬁrm these differences in efﬁcacy
and a possible correlation with antibody responses.
A very different approach has led to the development of the
only currently licensed anti-Leishmania vaccine product, Leish-
mune (for review see [57,58]). The vaccine is composed of a
yet to be fully deﬁned afﬁnity puriﬁed glycoproteic fraction of
L. donovani promastigotes, fucose-mannose-ligand (FML), for-
mulated with a saponin adjuvant. Leishmune is effective as a
prophylactic vaccine in the ﬁeld [59] and may also have an
impact on human VL incidence, when combined with the cull-
ing of seropositive animals [11]. Leishmune shows therapeu-
tic efﬁcacy in naturally infected, outbred dogs, particularly
when formulated with more saponin and in combination with
otherwise poorly effective drugs [60,61]. Leishmune seems
also to block transmission. The transmission blocking activity
may be a composite effect of (i) vaccinated dogs not having
parasites in their skin even when infected [62] and (ii) blocking
of parasite development in sandﬂies [63]. It is worth noting
that this vaccine apart from inducing mainly IgG2 antibodies
also stimulates both CD4+ and CD8+ T-cell responses that
correlate with clinical cure [64,65]. Induction of CD8+ T cells
may be related to adjuvant choice, as saponin is a critical com-
ponent of vaccines formulated as immunostimulatory com-
plexes (ISCOMs [66]). Recently, a dominant antigen in the
FML complex, a secreted nucleoside hydrolase of 36 kDa, has
been shown in recombinant form or as a DNA vaccine to
reproduce some of the Leishmune effects in mice [58], with
the C-terminal domain bearing the required T-cell epitopes
[67]. The rather crudely deﬁned but nevertheless effective Le-
ishmune vaccine may therefore become replaced by a syn-
thetic product comprising its active ingredients [58].
Similar to the situation in human VL patients, symptomatic
disease in dogs is correlated with a ‘suppressive’ pattern of T-
cell responses, with a dominant role for IL-10 in ongoing, non-
protective immune responses [68,69]. In view of this similarity
between HVL and CVL, the fact that Leishmune has shown
promise as a therapeutic vaccine in CVL is encouraging. The
therapeutic efﬁcacy in CVL of Leish-110f, which induces mainly
B-cell and CD4+ T-cell responses, was indistinguishable from
the effect of the MPL-SE adjuvants alone [54]. This may suggest
that a therapeutic vaccine against HVL should, akin to CVL,
aim to induce both CD4+ and CD8+ T cells. Findings in several
preclinical models [70–72] support this view.
Vaccine Platforms
As mentioned, the deﬁnition of correlates of immunity to
VL is still not very robust but, at the level of an individual,
protection is likely to depend on antigen-speciﬁc CD4+ and
CD8+ T cells able to activate or kill macrophages that are
or may become infected. However, the induction of robust
T-cell-mediated immunity, in particular involving CD8+ T
cells, remains a general challenge for vaccine developers.
To induce the latter, live vectored vaccines based on bacte-
rial [73] and viral platforms [74] or vaccines based on
recombinant DNA [75,76] are probably most promising
and are in clinical development against several diseases. A
series of clinical trials exploiting experimental infection of
volunteers with P. falciparum malaria has provided much
insight into the promises and challenges of these
approaches [74]. Preclinical experience in other models of
leishmaniasis with recombinant adenovirus [77,78], vaccinia
virus [79–81], DNA [82–84] and attenuated Salmonella
[85–87] suggest that these carriers should also be explored
against HVL.
Ag Discovery in the Post-genomic Era
(Reverse Vaccinology)
While the choice of adjuvant/carrier and formulation is criti-
cal for the performance of a vaccine, providing the key cues
to instruct appropriate cell-mediated immunity, the selection
of antigens is no less important. Problematically, T cells rec-
ognize protein fragments (peptide epitopes) bound to major
histocompatibility (MHC) proteins that are polymorphic in a
population for which the vaccine is to be developed. In the
examples discussed above, two very different antigen-discov-
ery approaches were used. Antigens contained in Leish-
mune were isolated by chemical fractionation of parasite
material and not by immunoscreening. In contrast, Leish-111f
antigens were identiﬁed because they reacted with speciﬁc Ig
in sera or T cells generated from patients or Montenegro
skin-test-positive individuals in high throughput screening of
gene-expression libraries [88–91]. This approach was also
applied to identify B and T-cell antigens recognized during
Leishmania infections in mice (e.g. [92,93]) and, for Leish-
111f, in patients [88–91]. Other key antigens currently in late
stage preclinical development have been selected based lar-
gely on serendipity, after functional testing as vaccine candi-
dates (e.g. HASPB [55]).
With multiple genome sequences now available and high
coverage proteome data available [94–97], the vaccine anti-
gen discovery process has entered the era of reverse vacci-
nology [4,98]. For example, proteins featuring tandem
repeats were originally identiﬁed by screening expression
libraries with patient sera [89] but this approach has now
been ‘reversed’ by screening protozoan genomes for genes
encoding proteins with tandem repeats and subsequently
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verifying their antigenicity [99]. However, to date very few
studies have used a purely reversed approach starting from
genome, proteome or transcriptome data to derive and test
candidate vaccine antigens.
A prerequisite of reverse vaccinology is that criteria can be
identiﬁed to design an algorithm for vaccine candidate selec-
tion. Several studies [100–103] provide support for selection
based on protein expression in the amastigote form, relative
protein abundance and subcellular localization. It is reasonable
to demand in addition that antigens show sequence conserva-
tion across parasite species and lack of homology to a vaccine
recipient species (i.e. human or canine hosts). The last three
criteria can be addressed using bioinformatics tools, genome
information and sequence data repositories. Proteomic data
are publicly available that provide a resource for the ﬁrst two
criteria [95–97]. Furthermore, bioinformatic analysis has veri-
ﬁed that protein abundance is correlated with codon bias,
resulting in higher translational efﬁciency [96,104]. Thus, even
in the absence of proteomic evidence for the abundance of a
particular protein (true for most membrane proteins) biased
codon usage in the respective gene combined with mRNA
abundance data from transcriptome analyses [105–107] can
serve as a surrogate measure for relative protein abundance.
Our unpublished experience with such a reverse vaccinology
approach (Fig. 2) has so far identiﬁed two novel vaccine candi-
dates from L. donovani that have shown promise in EVL (and
CL).
The need to induce or boost speciﬁc CD8+ T cells to
protect against EVL [38,70,72,108] is reﬂected by the inclu-
sion of predicted CD8+ T-cell epitopes in the genomic
resource TriTrypDB (Kinetoplastid Genomics Resource,
http://tritrypdb.org/tritrypdb/). Veriﬁed epitopes listed in this
resource were computed by the ‘Immune Epitope Database
and Analysis Resource’ (IEDB, http://www.immuneepi-
tope.org/), and experimentally conﬁrmed epitopes are listed
with their respective sequence, source, method of identiﬁca-
tion and reference. For non-included antigens, more than 30
programs predicting potential T-cell epitopes, mostly based
on MHC-binding algorithms, are available on the Internet. A
comparative study [109] assessed performance and reliability
of the different algorithms and revealed that matrix-based
programs (e.g. BIMAS and SYFPEITHI) were outperformed
by non-linear predictors such as NetMHC that are based on
artiﬁcial neural networks (ANN [110,111] http://
www.cbs.dtu.dk/services/NetMHC/). To predict binding pep-
tides, information on MHC polymorphisms is required. In
dogs, these are not well characterized and hence this kind of
bioinformatics may offer little to reﬁne antigen selection
approaches for CVL vaccines. However, for HVL vaccines,
data on relevant human populations is available. For example,
the population of India is highly diverse with several thou-
sand endogamous groups [112] but HVL is endemic in only
three states in the north of India. Focusing on Bihar, where
90% of all cases of VL are reported, eastern Uttar Pradesh
and West Bengal, the composition of ethnic populations
becomes less complex. The Indian Genome Variation Con-
sortium established that the majority population of these
states is Caucasian (Uttar Pradesh, Bihar and admixture in
West Bengal) and Australoid (West Bengal) with mongoloid
inﬂuence. Accordingly the most common HLA class I alleles
FIG. 2. Flow chart of a reverse vaccina-
tion approach to identify novel antigens.
Depicted is a binary decision tree and
criteria to rank ORF products for
candidate antigen selection starting from
‘Omics’ datasets. **An exemplary analy-
sis of CAI values for all ORFs of the
L. major genome has been published in
Paape et al. Mol Cell Proteomics 2008; 7:
1688–1701.
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in this population are likely to be A*02, A*24, A*11 and
A*33 in the HLA-A locus and B*07, B*35, B*40, B*57 and
B*58 in the HLA-B locus. Thus, for the purpose of predicting
vaccine antigen-derived HLA binding epitopes for people at
risk in India, analysis may be limited to these most common
haplotypes. HLA subtype distributions in populations at risk
in other regions such as Bangladesh or Nepal will eventually
also have to be considered. Of note, the normally most
ubiquitous Caucasian allele A*0201 is absent and replaced
with the more frequent A*0211 in the Indian population.
Thus, the reverse vaccinology approach outlined above may
be suited to improving the hit rate of protective antigen dis-
covery that was comparatively low in the few studies that
exploited early genomic information on the parasite
[83,84,113].
Future Directions and Vaccine Trial
Strategies
Recent reviews have highlighted the general considerations
that underlie the future development of a Leishmania vaccine
[1] and many of these can be applied to vaccines against
HVL. However, whilst there are arguments for the develop-
ment of new preclinical models of HVL, the incorporation of
natural sandﬂy challenge [114], the identiﬁcation of a greater
range of antigen candidates with broad species coverage, and
a greater understanding of the immunology of protective
immunity, these arguments should be balanced by the need
to develop a stronger base in clinical vaccinology, akin to
that seen for other diseases. This end is only likely to be
accomplished by an accelerated programme of well-deﬁned
clinical trials, and in this context the use of therapeutic vac-
cine trials as a ﬁrst step has much to offer.
Transparency Declaration
P. M. Kaye and T. Aebischer acknowledge the support from
the Wellcome Trust (Wellcome Trust Translation Award
#085879) in developing a vaccine against VL and a Marie
Curie Excellence Grant (MC-EXT 25435 to T. Aebischer)
from the European Commission. The authors declare no
other commercial interest.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Human and canine VL vaccination trials asses-
sing submit, 2nd generation vaccines.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
References
1. Costa CHN, Peters NC, Maruyama SR et al. Vaccines for the leish-
maniases: proposals for a research agenda. PLoS Negl Trop Dis 2011;
5: e943.
2. Kedzierski L. Leishmaniasis Vaccine: Where are We Today? J Glob
Infect Dis 2010; 2: 177–185.
3. Okwor I, Uzonna J. Vaccines and vaccination strategies against
human cutaneous leishmaniasis. Hum Vaccin 2009; 5: 291–301.
4. Dumonteil E. Vaccine development against Trypanosoma cruzi and
Leishmania species in the post-genomic era. Infect Genet Evol 2009; 9:
1075–1082.
5. Noazin S, Khamesipour A, Moulton LH et al. Efﬁcacy of killed
whole-parasite vaccines in the prevention of leishmaniasis: a meta-
analysis. Vaccine 2009; 27: 4747–4753.
6. Coler RN, Reed SG. Second-generation vaccines against leishmania-
sis. Trends Parasitol 2005; 21: 244–249.
7. Murray HW, Berman JD, Davies CR et al. Advances in leishmaniasis.
Lancet 2005; 366: 1561–1577.
8. Lukes J, Mauricio IL, Schonian G et al. Evolutionary and geographical
history of the Leishmania donovani complex with a revision of cur-
rent taxonomy. Proc Natl Acad Sci USA 2007; 104: 9375–9380.
9. Alvar J, Canavate C, Molina R et al. Canine leishmaniasis. Adv Parasi-
tol 2004; 57: 1–88.
10. Reis AB, Giunchetti RC, Carrillo E et al. Immunity to Leishmania and
the rational search for vaccines against canine leishmaniasis. Trends
Parasitol 2010; 26: 341–349.
11. Palatnik-de-Sousa CB, Silva-Antunes I, Morgado AA et al. Decrease
of the incidence of human and canine visceral leishmaniasis after dog
vaccination with Leishmune in Brazilian endemic areas. Vaccine 2009;
27: 3505–3512.
12. Singh SP, Picado A, Boelaert M et al. The epidemiology of Leishmania
donovani infection in high transmission foci in India. Trop Med Int
Health 2010; 15 (suppl 2): 12–20.
13. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are
the needs for diagnosis, treatment and control? Nat Rev Microbiol
2007; 5: 873–882.
14. Salotra P, Sreenivas G, Beena KR et al. Parasite detection in patients
with post kala-azar dermal leishmaniasis in India: a comparison
between molecular and immunological methods. J Clin Pathol 2003;
56: 840–843.
15. Zijlstra EE, Musa AM, Khalil EA et al. Post-kala-azar dermal leishman-
iasis. Lancet Infect Dis 2003; 3: 87–98.
16. Courtenay O, Quinnell RJ, Garcez LM et al. Infectiousness in a
cohort of brazilian dogs: why culling fails to control visceral leish-
maniasis in areas of high transmission. J Infect Dis 2002; 186: 1314–
1320.
17. Soares MR, de Mendonc¸a IL, do Bonﬁm JM et al. Canine visceral
leishmaniasis in Teresina, Brazil: relationship between clinical fea-
tures and infectivity for sand ﬂies. Acta Trop 2011; 117: 6–9.
18. Michalsky EM, Rocha MF, da Rocha Lima AC et al. Infectivity of
seropositive dogs, showing different clinical forms of leishmaniasis,
CMI Kaye and Aebischer Visceral leishmaniasis 1467
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1462–1470
to Lutzomyia longipalpis phlebotomine sand ﬂies. Vet Parasitol 2007;
147: 67–76.
19. Stager S, Joshi T, Bankoti R. Immune evasive mechanisms contribut-
ing to persistent Leishmania donovani infection. Immunol Res 2010; 47:
14–24.
20. Nylen S, Gautam S. Immunological perspectives of leishmaniasis. J
Glob Infect Dis 2010; 2: 135–146.
21. Sharma U, Singh S. Immunobiology of leishmaniasis. Indian J Exp Biol
2009; 47: 412–423.
22. Kaye PM, Svensson M, Ato M et al. The immunopathology of experi-
mental visceral leishmaniasis. Immunol Rev 2004; 201: 239–253.
23. Zijlstra EE, El-Hassan AM. Leishmaniasis in Sudan. Visceral leishmani-
asis. Trans R Soc Trop Med Hyg 2001; 95 (suppl 1): S27–S58.
24. Deak E, Jayakumar A, Cho KW et al. Murine visceral leishmaniasis:
IgM and polyclonal B-cell activation lead to disease exacerbation. Eur
J Immunol 2010; 40: 1355–1368.
25. Smelt SC, Cotterell SE, Engwerda CR et al. B cell-deﬁcient mice are
highly resistant to Leishmania donovani infection, but develop neutro-
phil-mediated tissue pathology. J Immunol 2000; 164: 3681–3688.
26. Halstead SB, Mahalingam S, Marovich MA et al. Intrinsic antibody-
dependent enhancement of microbial infection in macrophages: dis-
ease regulation by immune complexes. Lancet Infect Dis 2010; 10:
712–722.
27. Chu N, Thomas BN, Patel SR et al. IgG1 is pathogenic in Leishmania
mexicana infection. J Immunol 2010; 185: 6939–6946.
28. Amanna IJ, Slifka MK. Contributions of humoral and cellular immu-
nity to vaccine-induced protection in humans. Virology 2011; 411:
206–215.
29. Thalhofer CJ, Chen Y, Sudan B et al. Leukocytes inﬁltrate the skin
and draining lymph nodes in response to the protozoan Leishmania
infantum chagasi. Infect Immun 2011; 79: 108–117.
30. Beattie L, Peltan A, Maroof A et al. Dynamic imaging of experimental
Leishmania donovani-induced hepatic granulomas detects Kupffer cell-
restricted antigen presentation to antigen-speciﬁc CD8 T cells. PLoS
Pathog 2010; 6: e1000805.
31. Murray HW, Xiang Z, Ma X. Responses to Leishmania donovani in
mice deﬁcient in both phagocyte oxidase and inducible nitric oxide
synthase. Am J Trop Med Hyg 2006; 74: 1013–1015.
32. Phillips R, Svensson M, Aziz N et al. Innate killing of Leishmania dono-
vani by macrophages of the splenic marginal zone requires IRF-7.
PLoS Pathog 2010; 6: e1000813.
33. Kaye PM, Curry AJ, Blackwell JM. Differential production of Th1-
and Th2-derived cytokines does not determine the genetically con-
trolled or vaccine-induced rate of cure in murine visceral leishmania-
sis. J Immunol 1991; 146: 2763–2770.
34. Stager S, Alexander J, Carter KC et al. Both interleukin-4 (IL-4) and
IL-4 receptor alpha signaling contribute to the development of hepa-
tic granulomas with optimal antileishmanial activity. Infect Immun
2003; 71: 4804–4807.
35. Stager S, Maroof A, Zubairi S et al. Distinct roles for IL-6 and IL-
12p40 in mediating protection against Leishmania donovani and the
expansion of IL-10+ CD4+ T cells. Eur J Immunol 2006; 36: 1764–
1771.
36. Nylen S, Maurya R, Eidsmo L et al. Splenic accumulation of IL-10
mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T
cells in human visceral leishmaniasis. J Exp Med 2007; 204: 805–
817.
37. Ganguly S, Mukhopadhyay D, Das NK et al. Enhanced lesional Foxp3
expression and peripheral anergic lymphocytes indicate a role for
regulatory T cells in Indian post-kala-azar dermal leishmaniasis. J
Invest Dermatol 2010; 130: 1013–1022.
38. Polley R, Stager S, Prickett S et al. Adoptive immunotherapy against
experimental visceral leishmaniasis with CD8+ T cells requires the
presence of cognate antigen. Infect Immun 2006; 74: 773–776.
39. Dalton JE, Maroof A, Owens BM et al. Inhibition of receptor tyro-
sine kinases restores immunocompetence and improves immune-
dependent chemotherapy against experimental leishmaniasis in mice.
J Clin Invest 2010; 120: 1204–1216.
40. Dalton JE, Kaye PM. Immunomodulators: use in combined therapy
against leishmaniasis. Expert Rev Anti Infect Ther 2010; 8: 739–742.
41. Murray HW, Hariprashad J, Fichtl RE. Models of relapse of experi-
mental visceral leishmaniasis. J Infect Dis 1996; 173: 1041–1043.
42. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease
burden attributable to leishmaniasis. PLoS Negl Trop Dis 2008; 2:
e313.
43. Mathers CD, Ezzati M, Lopez AD. Measuring the burden of
neglected tropical diseases: the global burden of disease framework.
PLoS Negl Trop Dis 2007; 1: e114.
44. Meheus F, Balasegaram M, Olliaro P et al. Cost-Effectiveness analysis
of combination therapies for visceral leishmaniasis in the Indian sub-
continent. PLoS Negl Trop Dis 2010; 4: e818.
45. Sarnoff R, Desai J, Desjeux P et al. The economic impact of visceral
leishmaniasis on rural households in one endemic district of Bihar,
India. Trop Med Int Health 2010; 15 (suppl 2): 42–49. Epub 2010 May
6.
46. Khamesipour A, Dowlati Y, Asilian A et al. Leishmanization: use of
an old method for evaluation of candidate vaccines against leishmani-
asis. Vaccine 2005; 23: 3642–3648.
47. Nadim A, Javadian E, Tahvildar-Bidruni G et al. Effectiveness of leish-
manization in the control of cutaneous leishmaniasis. Bull Soc Pathol
Exot Filiales 1983; 76: 377–383.
48. El-On J. Current status and perspectives of the immunotherapy of
leishmaniasis. Isr Med Assoc J 2009; 11: 623–628.
49. Okwor I, Uzonna JE. Immunotherapy as a strategy for treatment of
leishmaniasis: a review of the literature. Immunotherapy 2009; 1:
765–776.
50. Badaro R, Lobo I, Munos A et al. Immunotherapy for drug-refractory
mucosal leishmaniasis. J Infect Dis 2006; 194: 1151–1159.
51. de Matos Guedes HL, Pinheiro RO, Chaves SP et al. Serine prote-
ases of Leishmania amazonensis as immunomodulatory and disease-
aggravating components of the crude LaAg vaccine. Vaccine 2010; 28:
5491–5496.
52. Nascimento E, Fernandes DF, Vieira EP et al. A clinical trial to evalu-
ate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine
when used in combination with meglumine antimoniate for the
treatment of cutaneous leishmaniasis. Vaccine 2010; 28: 6581–6587.
53. Campos-Neto A, Webb JR, Greeson K et al. Vaccination with plas-
mid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers
protection against Leishmania major infection in susceptible BALB/c
mice. Infect Immun 2002; 70: 2828–2836.
54. Miret J, Nascimento E, Sampaio W et al. Evaluation of an immun-
ochemotherapeutic protocol constituted of N-methyl meglumine an-
timoniate (Glucantime) and the recombinant Leish-110f + MPL-SE
vaccine to treat canine visceral leishmaniasis. Vaccine 2008; 26:
1585–1594.
55. Stager S, Smith DF, Kaye PM. Immunization with a recombinant
stage-regulated surface protein from Leishmania donovani induces
protection against visceral leishmaniasis. J Immunol 2000; 165: 7064–
7071.
56. Moreno J, Nieto J, Masina S et al. Immunization with H1, HASPB1
and MML Leishmania proteins in a vaccine trial against experimental
canine leishmaniasis. Vaccine 2007; 25: 5290–5300.
57. Dantas-Torres F. Leishmune vaccine: the newest tool for prevention
and control of canine visceral leishmaniosis and its potential as a
transmission-blocking vaccine. Vet Parasitol 2006; 141: 1–8.
58. Palatnik-de-Sousa CB, Barbosa AF, Oliveira SM et al. FML vaccine
against canine visceral leishmaniasis: from second-generation to syn-
thetic vaccine. Expert Rev Vaccines 2008; 7: 833–851.
1468 Clinical Microbiology and Infection, Volume 17 Number 10, October 2011 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1462–1470
59. Borja-Cabrera GP, Correia Pontes NN, da Silva VO et al. Long last-
ing protection against canine kala-azar using the FML-QuilA saponin
vaccine in an endemic area of Brazil (Sao Goncalo do Amarante,
RN). Vaccine 2002; 20: 3277–3284.
60. Borja-Cabrera GP, Santos FN, Santos FB et al. Immunotherapy with
the saponin enriched-Leishmune vaccine versus immunochemothera-
py in dogs with natural canine visceral leishmaniasis. Vaccine 2010;
28: 597–603.
61. Borja-Cabrera GP, Cruz MA, Paraguai deSE et al. Effective immuno-
therapy against canine visceral leishmaniasis with the FML-vaccine.
Vaccine 2004; 22: 2234–2243.
62. Nogueira FS, Moreira MA, Borja-Cabrera GP et al. Leishmune vac-
cine blocks the transmission of canine visceral leishmaniasis: absence
of Leishmania parasites in blood, skin and lymph nodes of vaccinated
exposed dogs. Vaccine 2005; 23: 4805–4810.
63. Saraiva EM, de Figueiredo BA, Santos FN et al. The FML-vaccine
(Leishmune) against canine visceral leishmaniasis: a transmission
blocking vaccine. Vaccine 2006; 24: 2423–2431.
64. Araujo MS, de Andrade RA, Vianna LR et al. Despite Leishvaccine
and Leishmune trigger distinct immune proﬁles, their ability to acti-
vate phagocytes and CD8+ T-cells support their high-quality immu-
nogenic potential against canine visceral leishmaniasis. Vaccine 2008;
26: 2211–2224.
65. Araujo MS, de Andrade RA, Sathler-Avelar R et al. T-cell-derived
cytokines, nitric oxide production by peripheral blood monocytes
and seric anti-Leishmania chagasi IgG subclass patterns following
immunization against canine visceral leishmaniasis using Leishvaccine
and Leishmune. Vaccine 2009; 27: 1008–1017.
66. Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 2009;
27: 4388–4401.
67. Nico D, Claser C, Borja-Cabrera GP et al. Adaptive immunity
against Leishmania nucleoside hydrolase maps its c-terminal domain
as the target of the CD4+ T cell-driven protective response. PLoS
Negl Trop Dis 2010; 4: e866.
68. Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human vis-
ceral leishmaniasis. Trends Immunol 2007; 28: 378–384.
69. Carrillo E, Moreno J. Cytokine proﬁles in canine visceral leishmania-
sis. Vet Immunol Immunopathol 2009; 128: 67–70.
70. Stager S, Alexander J, Kirby AC et al. Natural antibodies and com-
plement are endogenous adjuvants for vaccine-induced CD8+ T-cell
responses. Nat Med 2003; 9: 1287–1292.
71. Gurunathan S, Sacks DL, Brown DR et al. Vaccination with DNA
encoding the immunodominant LACK parasite antigen confers pro-
tective immunity to mice infected with Leishmania major. J Exp Med
1997; 186: 1137–1147.
72. Basu R, Bhaumik S, Haldar AK et al. Hybrid cell vaccination resolves
Leishmania donovani infection by eliciting a strong CD8+ cytotoxic
T-lymphocyte response with concomitant suppression of interleu-
kin-10 (IL-10) but not IL-4 or IL-13. Infect Immun 2007; 75: 5956–
5966.
73. Levine MM. Can needle-free administration of vaccines become the
norm in global immunization? Nat Med 2003; 9: 99–103.
74. Hill AV, Reyes-Sandoval A, O’Hara G et al. Prime-boost vectored
malaria vaccines: progress and prospects. Hum Vaccin 2010; 6: 78–
83.
75. Beckett CG, Tjaden J, Burgess T et al. Evaluation of a prototype
dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2010; 29:
960–968.
76. Palma P, Romiti ML, Li PG et al. The PEDVAC trial: preliminary data
from the ﬁrst therapeutic DNA vaccination in HIV-infected children.
Vaccine 2011; doi:10.1016/j.vaccine.2010.12.058. [Epub head of
print].
77. Darrah PA, Patel DT, De Luca PM et al. Multifunctional TH1 cells
deﬁne a correlate of vaccine-mediated protection against Leishmania
major. Nat Med 2007; 13: 843–850.
78. Darrah PA, Hegde ST, Patel DT et al. IL-10 production differentially
inﬂuences the magnitude, quality, and protective capacity of Th1
responses depending on the vaccine platform. J Exp Med 2010; 207:
1421–1433.
79. Carson C, Antoniou M, Ruiz-Arguello MB et al. A prime/boost
DNA/Modiﬁed vaccinia virus Ankara vaccine expressing recombinant
Leishmania DNA encoding TRYP is safe and immunogenic in outbred
dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine 2009;
27: 1080–1086.
80. Ramos I, Alonso A, Marcen JM et al. Heterologous prime-boost vac-
cination with a non-replicative vaccinia recombinant vector express-
ing LACK confers protection against canine visceral leishmaniasis
with a predominant Th1-speciﬁc immune response. Vaccine 2008;
26: 333–344.
81. Perez-Jimenez E, Kochan G, Gherardi MM et al. MVA-LACK as a
safe and efﬁcient vector for vaccination against leishmaniasis.
Microbes Infect 2006; 8: 810–822.
82. Mendez S, Gurunathan S, Kamhawi S et al. The potency and durabil-
ity of DNA- and protein-based vaccines against Leishmania major
evaluated using low-dose, intradermal challenge. J Immunol 2001;
166: 5122–5128.
83. Almeida R, Norrish A, Levick M et al. From genomes to vaccines:
Leishmania as a model. Philos Trans R Soc Lond B Biol Sci 2002; 357:
5–11.
84. Stober CB, Lange UG, Roberts MT et al. From genome to vaccines
for leishmaniasis: screening 100 novel vaccine candidates against
murine Leishmania major infection. Vaccine 2006; 24: 2602–2616.
85. Lange UG, Mastroeni P, Blackwell JM et al. DNA-Salmonella enterica
serovar Typhimurium primer-booster vaccination biases towards T
helper 1 responses and enhances protection against Leishmania major
infection in mice. Infect Immun 2004; 72: 4924–4928.
86. McSorley SJ, Xu D, Liew FY. Vaccine efﬁcacy of Salmonella strains
expressing glycoprotein 63 with different promoters. Infect Immun
1997; 65: 171–178.
87. Yang DM, Fairweather N, Button LL et al. Oral Salmonella typhimuri-
um (AroA-) vaccine expressing a major leishmanial surface protein
(gp63) preferentially induces T helper 1 cells and protective immu-
nity against leishmaniasis. J Immunol 1990; 145: 2281–2285.
88. Skeiky YA, Kennedy M, Kaufman D et al. LeIF: a recombinant Leish-
mania protein that induces an IL-12-mediated Th1 cytokine proﬁle. J
Immunol 1998; 161: 6171–6179.
89. Goto Y, Coler RN, Guderian J et al. Cloning, characterization, and
serodiagnostic evaluation of Leishmania infantum tandem repeat pro-
teins. Infect Immun 2006; 74: 3939–3945.
90. Skeiky YA, Guderian JA, Benson DR et al. A recombinant Leishmania
antigen that stimulates human peripheral blood mononuclear cells to
express a Th1-type cytokine proﬁle and to produce interleukin 12. J
Exp Med 1995; 181: 1527–1537.
91. Probst P, Stromberg E, Ghalib HW et al. Identiﬁcation and charac-
terization of T cell-stimulating antigens from Leishmania by CD4 T
cell expression cloning. J Immunol 2001; 166: 498–505.
92. Mougneau E, Altare F, Wakil AE et al. Expression cloning of a pro-
tective Leishmania antigen. Science 1995; 268: 563–566.
93. Campos-Neto A, Soong L, Cordova JL et al. Cloning and expression
of a Leishmania donovani gene instructed by a peptide isolated from
major histocompatibility complex class II molecules of infected mac-
rophages. J Exp Med 1995; 182: 1423–1433.
94. Ivens AC, Peacock CS, Worthey EA et al. The genome of the kine-
toplastid parasite, Leishmania major. Science 2005; 309: 436–442.
CMI Kaye and Aebischer Visceral leishmaniasis 1469
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1462–1470
95. Rosenzweig D, Smith D, Opperdoes F et al. Retooling Leishmania
metabolism: from sand ﬂy gut to human macrophage. FASEB J 2008;
22: 590–602.
96. Paape D, Lippuner C, Schmid M et al. Transgenic, ﬂuorescent Leish-
mania mexicana allow direct analysis of the proteome of intracellular
amastigotes. Mol Cell Proteomics 2008; 7: 1688–1701.
97. Paape D, Barrios-Llerena ME, Le BT et al. Gel free analysis of the
proteome of intracellular Leishmania mexicana. Mol Biochem Parasitol
2010; 169: 108–114.
98. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000; 3: 445–
450.
99. Goto Y, Coler RN, Reed SG. Bioinformatic identiﬁcation of tandem
repeat antigens of the Leishmania donovani complex. Infect Immun
2007; 75: 846–851.
100. Aebischer T, Wolfram M, Patzer SI et al. Subunit vaccination of mice
against new world cutaneous leishmaniasis: comparison of three
proteins expressed in amastigotes and six adjuvants. Infect Immun
2000; 68: 1328–1336.
101. Wolfram M, Fuchs M, Wiese M et al. Antigen presentation by Leish-
mania mexicana-infected macrophages: activation of helper T cells by a
model parasite antigen secreted into the parasitophorous vacuole or
expressed on the amastigote surface. Eur J Immunol 1996; 26: 3153–
3162.
102. Prickett S, Gray PM, Colpitts SL et al. In vivo recognition of ovalbu-
min expressed by transgenic Leishmania is determined by its subcel-
lular localization. J Immunol 2006; 176: 4826–4833.
103. Overath P, Aebischer T. Antigen presentation by macrophages har-
boring intravesicular pathogens. Parasitol Today 1999; 15: 325–332.
104. Horn D. Codon usage suggests that translational selection has a
major impact on protein expression in trypanosomatids. BMC Ge-
nomics 2008; 9: 2.
105. Holzer TR, McMaster WR, Forney JD. Expression proﬁling by
whole-genome interspecies microarray hybridization reveals differen-
tial gene expression in procyclic promastigotes, lesion-derived am-
astigotes, and axenic amastigotes in Leishmania mexicana. Mol
Biochem Parasitol 2006; 146: 198–218.
106. Leifso K, Cohen-Freue G, Dogra N et al. Genomic and proteomic
expression analysis of Leishmania promastigote and amastigote life
stages: the Leishmania genome is constitutively expressed. Mol Bio-
chem Parasitol 2007; 152: 35–46.
107. Lahav T, Sivam D, Volpin H et al. Multiple levels of gene regulation
mediate differentiation of the intracellular pathogen Leishmania.
FASEB J 2011; 25: 515–525.
108. Mary C, Auriault V, Faugere B et al. Control of Leishmania infantum
infection is associated with CD8+ and gamma interferon- and inter-
leukin-5-producing CD4+ antigen-speciﬁc T cells. Infect Immun 1999;
67: 5559–5566.
109. Lin HH, Zhang GL, Tongchusak S et al. Evaluation of MHC-II peptide
binding prediction servers: applications for vaccine research. BMC
Bioinformatics 2008; 9 (suppl 12): S22.
110. Buus S, Lauemoller SL, Worning P et al. Sensitive quantitative pre-
dictions of peptide-MHC binding by a ‘Query by Committee’ artiﬁ-
cial neural network approach. Tissue Antigens 2003; 62: 378–384.
111. Nielsen M, Lundegaard C, Worning P et al. Reliable prediction of T-
cell epitopes using neural networks with novel sequence representa-
tions. Protein Sci 2003; 12: 1007–1017.
112. The Indian Genome Variation database (IGVdb): a project overview.
Hum Genet 2005; 118: 1–11.
113. Stober CB. From genomes to vaccines for leishmaniasis. Methods
Mol Biol 2004; 270: 423–438.
114. Peters NC, Kimblin N, Secundino N et al. Vector transmission of
leishmania abrogates vaccine-induced protective immunity. PLoS Pa-
thog 2009; 5: e1000484.
1470 Clinical Microbiology and Infection, Volume 17 Number 10, October 2011 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1462–1470
